Search results for "METASTATIC MELANOMA"

showing 3 items of 23 documents

Metastatic Melanoma of the Tongue: A Rare Case

2012

Not available

medicine.medical_specialtyHistologyMetastatic melanomabusiness.industryMelanomaDermatologyGeneral Medicinemedicine.diseaseoral melanomaDermatologyPathology and Forensic Medicinemedicine.anatomical_structureSettore MED/28 - Malattie OdontostomatologicheTongueRare caseMedicineTongue NeoplasmbusinessActas Dermo-Sifiliográficas
researchProduct

Regression of multiple melanocytic nevi associated with nivolumab treatment for metastatic melanoma

2018

medicine.medical_specialtySkin NeoplasmsMetastatic melanomaBiopsyTreatment outcomeDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineX ray computedBiopsymedicineHumansNevusSkin pathologyMelanomaSkinNevus Pigmentedmedicine.diagnostic_testbusiness.industryMelanomaLiver NeoplasmsMiddle Agedmedicine.diseaseDermatologyNivolumabTreatment Outcome030220 oncology & carcinogenesisFemaleNivolumabTomography X-Ray ComputedbusinessInternational Journal of Dermatology
researchProduct

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

2016

Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Advers…

safetyCancer Researchmedicine.drug_classmedicine.medical_treatmentMedizinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerimmunogenicityImmunostimulant03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerCancer immunotherapymedicine1506030304 developmental biologyOriginal ResearchPRAME antigen0303 health sciencesPRAMEcancer immunotherapybusiness.industryMelanomaImmunogenicityCancermedicine.disease3. Good healthOncology030220 oncology & carcinogenesisImmunologyChillsmedicine.symptombusinessmetastatic melanoma
researchProduct